Sara Norris
Family Medicine · Opelika, ALNPI 1568071652
Payments from drug & device makers
Across 426 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- AbbVie$944
- Novo Nordisk$655
- Pfizer$563
- Amgen$506
- plus $3K from 27 others
What the payments were for
- Food & beverage$8,178100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 40 | $1,263 |
| GSK | 57 | $1,089 |
| AbbVie | 65 | $944 |
| Novo Nordisk | 33 | $655 |
| Pfizer | 38 | $563 |
| Amgen | 14 | $506 |
| Johnson & Johnson | 20 | $378 |
| Astellas Pharma US Inc | 21 | $353 |
| Novartis | 23 | $331 |
| Abbott | 18 | $272 |
| Lilly USA, LLC | 10 | $259 |
| Corcept Therapeutics | 8 | $147 |
| Amarin Pharma, Inc. | 9 | $143 |
| Scilex Pharmaceuticals Inc. | 9 | $140 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $135 |
| Mylan Specialty L.p. | 7 | $133 |
| Merck | 7 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $101 |
| Paratek Pharmaceuticals, Inc. | 1 | $96 |
| Sanofi-aventis U.S. LLC | 5 | $73 |
| Xeris Pharmaceuticals, Inc. | 3 | $69 |
| Lundbeck LLC | 4 | $67 |
| Phathom Pharmaceuticals, Inc. | 4 | $66 |
| Vanda Pharmaceuticals Inc. | 2 | $59 |
| Corium, LLC | 2 | $48 |
| Shield Therapeutics Inc | 3 | $44 |
| KCI USA, Inc. | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,178 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 144 | $151,876 |
| OzempicSemaglutide | 117 | $120,633 |
| JardianceEmpagliflozin | 96 | $66,033 |
| FarxigaDapagliflozin Propanediol | 76 | $57,274 |
| EliquisApixaban | 52 | $43,183 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $39,920 |
| JanuviaSitagliptin Phosphate | 47 | $33,914 |
| MyrbetriqMirabegron | 51 | $25,485 |
| RybelsusSemaglutide | 22 | $20,402 |
| LinzessLinaclotide | 28 | $16,984 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,132 |
| EntrestoSacubitril/Valsartan | 13 | $10,784 |
| VascepaIcosapent Ethyl | 24 | $10,212 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,551 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $8,154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $259 | $151,876144 claims |
| Novo NordiskOzempic, Rybelsus | $655 | $141,035139 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,263 | $69,40596 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,089 | $48,47183 claims |
| PfizerEliquis | $563 | $43,18352 claims |
| MerckJanuvia | $105 | $33,91447 claims |
| Astellas Pharma US IncMyrbetriq | $353 | $25,48551 claims |
| AbbVieLinzess | $944 | $16,98428 claims |
| NovartisEntresto | $331 | $10,78413 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $140 | $1,67036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Opelika
- Sunil SharmaOpelika$17K
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.